Alnylam Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Alnylam Bundle
What is included in the product
Detailed Word Document
A comprehensive business model canvas tailored to Alnylam's strategy, organized into 9 blocks with insights.
Customizable Excel Spreadsheet
Quickly identify core components with a one-page business snapshot.
Preview Before You Purchase
Business Model Canvas
This Business Model Canvas preview is the complete package. The file you see here is the actual document you'll receive after purchase. Expect the same layout, content, and structure—ready for immediate use.
Business Model Canvas Template
Alnylam's RNAi: Decoding the Business Model Canvas!
Alnylam's Business Model Canvas centers on RNAi therapeutics, targeting unmet medical needs. Key partnerships with research institutions and biotech firms drive innovation. Their value proposition lies in pioneering novel treatments, focusing on genetic diseases. The revenue streams include product sales, royalties, and collaborations. Understand Alnylam's strategic components—download the full Business Model Canvas today!
Partnerships
Sanofi Collaboration
Alnylam's collaboration with Sanofi is key for Fitusiran. Sanofi is a partner for the development and commercialization of Fitusiran, an RNAi therapeutic for hemophilia. Sanofi expects FDA approval by March 28, 2025. This partnership allows Alnylam to use Sanofi's expertise and resources. The deal includes royalty revenue for Alnylam.
Vir Biotechnology Collaboration
Alnylam's collaboration with Vir Biotechnology focuses on Elebsiran, targeting chronic hepatitis B and delta. Vir plans a Phase 3 study for hepatitis delta and expects Phase 2 results for hepatitis B in 2025. This partnership leverages Vir's virology expertise, expanding Alnylam's reach. The global hepatitis B market was valued at $1.2 billion in 2023.
Regeneron Pharmaceuticals Collaboration
Alnylam's collaboration with Regeneron focuses on complement-mediated diseases, notably with cemdisiran. In 2024, Regeneron's Phase 3 ACCESS-1 trial showed positive results for pozelimab and cemdisiran in paroxysmal nocturnal hemoglobinuria (PNH). This partnership uses Regeneron's expertise, aiming for novel treatments. The 2023 R&D spend was $1.25B.
Novartis Collaboration
Alnylam's partnership with Novartis is crucial. It grants Novartis exclusive rights to commercialize RNAi therapeutics, including Leqvio, for hypercholesterolemia. Leqvio is approved in over 100 countries. This collaboration leverages Novartis's global reach and expertise.
- Leqvio generated $345 million in sales in 2023.
- Novartis has a strong presence in cardiovascular disease.
- The partnership expands Alnylam's market access.
- Ongoing studies aim to broaden Leqvio's label.
Roche Collaboration
Alnylam's collaboration with Roche is a cornerstone of its business strategy. They are working together on Zilebesiran, an RNAi therapeutic for hypertension, currently in Phase 2 trials, expanding the reach of RNAi. This collaboration is crucial for commercializing Zilebesiran effectively. Roche and Ascidian Therapeutics are also partnering on gene-editing technologies for neurological diseases.
- Alnylam's R&D expenses were $468.7 million in 2023, showing significant investment in partnerships.
- Roche's pharmaceuticals division generated CHF 44.6 billion in sales in 2023, highlighting the scale of the collaboration.
- The global hypertension treatment market is projected to reach $35.9 billion by 2029, underscoring the commercial potential of Zilebesiran.
Strategic Alliances Fueling Growth and Innovation
Alnylam's collaborations are strategic to drive drug development and market reach. Partnerships with Sanofi, Vir, and Regeneron focus on specific disease areas and shared expertise. Novartis's and Roche's collaborations provide commercialization and market access. These partnerships are vital for Alnylam's growth.
| Partner | Therapeutic Focus | 2023 Sales/R&D Spend |
|---|---|---|
| Sanofi | Fitusiran | N/A |
| Vir Biotechnology | Elebsiran | $1.2B (Hepatitis B Market) |
| Regeneron | Cemdisiran, Pozelimab | $1.25B (R&D Spend) |
| Novartis | Leqvio | $345M |
| Roche | Zilebesiran | CHF 44.6B (Pharmaceuticals) |
Activities
RNAi Therapeutic Development
Alnylam's key activities revolve around RNAi therapeutic development. They discover and develop RNAi-based medicines for various diseases. This includes extensive research, preclinical studies, and clinical trials. In 2024, Alnylam invested significantly in R&D, with expenses reaching approximately $1.4 billion. Their focus is on creating innovative medicines targeting genetic issues.
Clinical Trial Advancement
Alnylam's key activities include advancing its drug pipeline through clinical trials. Currently, Phase 3 trials are underway for nucresiran and zilebesiran. By the end of 2025, the company aims to have over 25 programs in clinical stages. This process is vital for gaining regulatory approvals and broadening RNAi technology's use.
Regulatory Approval Pursuit
Alnylam prioritizes regulatory approvals for its RNAi therapeutics. They actively work with agencies like the FDA. A key focus is getting vutrisiran approved, with a PDUFA date of March 23, 2025. This activity is vital for launching new treatments. In Q3 2024, Alnylam's total revenues were $334.1 million.
Commercialization and Market Access
Alnylam actively commercializes its RNAi therapeutics like ONPATTRO and AMVUTTRA worldwide. They build commercial infrastructure, focusing on market access. This involves negotiating pricing and reimbursement. They manage distribution and conduct marketing and sales. In 2024, Alnylam's product sales reached $1.2 billion.
- ONPATTRO sales grew, reaching $419 million in 2024.
- AMVUTTRA sales also increased, hitting $508 million in 2024.
- GIVLAARI and OXLUMO contributed to the revenue.
- Alnylam is expanding its global commercial presence.
Strategic Pipeline Expansion
Alnylam actively grows its pipeline through internal R&D and collaborations. By the end of 2025, they aim to file IND applications for four new Alnylam-led programs. This strategy ensures a steady stream of innovation and strengthens their RNAi leadership. In 2024, Alnylam's R&D expenses were significant, reflecting this focus.
- R&D spending is a key investment for Alnylam.
- Collaborations are vital for pipeline growth.
- IND filings are a critical milestone.
- Alnylam aims to maintain its RNAi leadership.
RNAi Pioneer: Trials, Approvals, and $927M Sales
Alnylam's key activities drive RNAi drug development, including research and clinical trials, with 25+ programs planned in clinical stages by 2025. Securing regulatory approvals, such as for vutrisiran with a March 2025 PDUFA date, is crucial. Commercialization efforts, like ONPATTRO and AMVUTTRA, are worldwide, with 2024 sales at $419 million and $508 million, respectively.
| Key Activity | Description | 2024 Data |
|---|---|---|
| R&D | Research and development of RNAi therapeutics | $1.4B R&D expenses |
| Clinical Trials | Advancing drug pipeline through clinical trials. | 25+ programs in clinical stages by the end of 2025. |
| Regulatory Approvals | Securing approvals from agencies like the FDA. | Vutrisiran PDUFA date: March 23, 2025 |
| Commercialization | Worldwide sales of ONPATTRO, AMVUTTRA, etc. | ONPATTRO $419M, AMVUTTRA $508M |
Resources
RNAi Technology Platform
Alnylam's RNAi technology platform is crucial, enabling genetic disease treatments. They've invested heavily in siRNA design, delivery, and manufacturing. This platform drives the discovery of new RNAi therapeutics. In 2024, Alnylam's R&D spending hit $1.3 billion, highlighting their platform investment.
Intellectual Property Portfolio
Alnylam's robust intellectual property (IP) portfolio, including patents and proprietary knowledge, safeguards its RNAi tech and product candidates. The company strategically manages its IP to maintain a competitive edge. In 2024, Alnylam's R&D spending was approximately $1.1 billion, reflecting its commitment to innovation and IP protection. This IP is essential for attracting investment and securing partnerships.
Clinical and Regulatory Expertise
Alnylam's Clinical and Regulatory Expertise is a vital resource, driven by a team that navigates the complexities of clinical trials and regulatory approvals. This expertise ensures that Alnylam's RNAi therapeutics meet rigorous standards. In 2024, the FDA approved several novel therapies based on complex regulatory processes, underscoring the need for expertise.
Global Commercial Infrastructure
Alnylam's global commercial infrastructure, encompassing sales, marketing, distribution, and market access, is vital for its approved products. The company has a presence in key global markets, enabling patient and healthcare provider reach. This infrastructure maximizes the commercial potential of its RNAi therapeutics. In 2024, Alnylam reported significant revenue growth, reflecting the importance of this resource.
- Global presence supports product launches and market penetration.
- Sales and marketing teams drive product adoption among healthcare professionals.
- Distribution networks ensure product availability to patients.
- Market access capabilities facilitate patient access and reimbursement.
Financial Resources
Alnylam's financial prowess is a cornerstone of its operations, enabling robust investments in research and commercialization. The company's substantial cash reserves and access to capital markets fuel its ambitious R&D pipeline and clinical trials. Revenue from approved products and strategic financing support continuous innovation and expansion within the RNAi therapeutics space.
- In Q3 2024, Alnylam reported over $2.4 billion in cash, cash equivalents, and marketable securities.
- Alnylam's 2024 revenue is projected to exceed $1.2 billion, driven by product sales.
- The company has secured multiple financing deals to support its long-term growth.
- Alnylam allocates a significant portion of its budget, over 40%, to research and development.
Global Infrastructure: Sales, Distribution, & Access
Alnylam's Global Commercial Infrastructure includes sales, marketing, distribution, and market access. This global presence is crucial for product launches and market penetration. Sales teams drive adoption, distribution ensures availability, and market access supports patient reimbursement.
| Aspect | Details | 2024 Data |
|---|---|---|
| Sales & Marketing | Promoting RNAi therapeutics | Revenue growth reflects effectiveness |
| Distribution | Product availability to patients | Expanded networks for global reach |
| Market Access | Patient access & reimbursement | Facilitating patient support programs |
Value Propositions
Targeted Genetic Therapies
Alnylam's value lies in its targeted RNAi therapies. These therapies silence specific genes, offering precise treatment. This precision surpasses symptom-focused traditional methods. Alnylam's approach has the potential to change lives. In 2024, Alnylam's net product revenues were $1.2 billion.
Innovative RNAi Technology
Alnylam's RNAi tech is a groundbreaking approach in drug dev. It offers a clinically validated method for creating transformative medicines, targeting diseases previously untreatable. This innovation makes Alnylam a biotech leader. In 2024, Alnylam's revenue was $1.07 billion, showcasing its tech's impact.
Improved Patient Outcomes
Alnylam's RNAi therapeutics significantly improve patient outcomes. Clinical trials show reduced mortality and hospitalizations. This boosts the quality of life for those with serious diseases. They are committed to innovation via a global infrastructure. In 2024, they showed positive results in various trials.
Commercial Success and Growth
Alnylam's commercial success is evident through its marketed products like ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. In 2024, these products generated significant revenue, driving substantial growth for the company. This financial strength supports Alnylam's mission to develop RNAi therapeutics, offering value to investors. The positive outlook for 2025 further solidifies its market position.
- 2024 revenue growth driven by ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO.
- Strong financial performance reflects successful commercialization.
- Positive 2025 outlook indicates continued growth.
- Supports development and commercialization of RNAi therapeutics.
Pipeline of Transformative Medicines
Alnylam's value proposition centers on its "Pipeline of Transformative Medicines." The company boasts a robust pipeline of investigational medicines, including numerous late-stage candidates. Alnylam plans to file at least four new INDs in 2025. This strategy fuels continued growth in RNAi therapeutics, targeting various unmet medical needs.
- Over 20 clinical programs.
- 10+ late-stage programs.
- ≥4 New INDs planned for 2025.
RNAi Revolution: Silencing Genes for Better Health
Alnylam offers targeted RNAi therapies that silence specific genes, improving patient outcomes. Their innovation focuses on developing medicines for previously untreatable diseases. Commercial success, highlighted by ONPATTRO and others, drives company growth. Alnylam's strong pipeline of medicines fuels continued growth, with plans for multiple new INDs in 2025.
| Value Proposition Element | Description | Supporting Data |
|---|---|---|
| Targeted Therapies | RNAi tech silences specific genes. | 2024 Net Product Revenues: $1.2B |
| Innovative Medicines | Transforms treatments for unmet needs. | Revenue: $1.07B in 2024 |
| Commercial Success | ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO products. | Positive 2025 Outlook |
Customer Relationships
Direct Sales Force Engagement
Alnylam's direct sales force is crucial for educating healthcare providers on its RNAi therapeutics. This approach allows for personalized interactions and relationship building. In 2024, Alnylam's SG&A expenses, including sales force costs, were approximately $1.3 billion. The sales team provides comprehensive support to healthcare professionals.
Health System Partnerships
Alnylam collaborates with healthcare systems to enhance patient access and results. These collaborations focus on workflow and care pathway solutions to streamline care coordination and reimbursement. For example, in 2024, Alnylam's partnerships helped streamline processes for over 50,000 patients. Alnylam aids in integrating evidence-based guidelines into electronic health solutions. This boosts medication access and enhances the patient experience.
Medical Affairs Support
Alnylam prioritizes robust medical affairs support, offering healthcare providers scientific data, educational resources, and clinical trial insights. This aids informed decisions on their products. RNAiScience.com serves US HCPs, with contact info for non-US inquiries. In 2024, Alnylam's medical affairs efforts included publications and presentations at key medical conferences, enhancing product understanding.
Patient Advocacy Programs
Alnylam's commitment to patient relationships is evident through its advocacy programs. These programs offer vital support to patients and families managing diseases targeted by Alnylam's therapies. They provide resources, education, and assistance to navigate treatment effectively. This patient-centric approach underscores Alnylam's dedication to improving patient lives. In 2024, Alnylam invested heavily in these programs, reflecting its values.
- Patient advocacy programs support patients and families.
- Resources, education, and support are provided.
- The focus is on improving patient outcomes.
- Alnylam invested in these programs in 2024.
Digital Engagement Platforms
Alnylam strategically uses digital platforms to connect with stakeholders. These include their website and social media, offering product details, trial updates, and company news. This digital presence is vital for sharing data, collecting insights, and fostering relationships with their audience. Effective digital engagement is key for Alnylam's success, especially with healthcare providers and patients. In 2024, Alnylam's social media saw a 15% rise in engagement.
- Website and Social Media: Primary channels for information.
- Information Dissemination: Sharing product details and clinical trial updates.
- Feedback and Relationship Building: Gathering insights from stakeholders.
- Engagement Metrics: 15% rise in social media engagement in 2024.
Building Connections: Sales, Digital, and Patient Focus
Alnylam cultivates relationships through direct sales, medical affairs, and digital platforms. Direct sales provide personalized support, with 2024 SG&A expenses at $1.3B. Collaborations with healthcare systems enhanced patient access. Patient advocacy programs and a digital presence are also key. In 2024, social media engagement rose 15%.
| Customer Relationship Type | Description | 2024 Metrics |
|---|---|---|
| Direct Sales | Educates healthcare providers, personalized interactions. | SG&A expenses approx. $1.3B |
| Healthcare System Collaborations | Enhances patient access and streamlined processes. | Partnerships supported 50,000+ patients. |
| Medical Affairs | Offers scientific data, education, and trial insights. | Publications at medical conferences. |
Channels
Specialty Pharmacies
Alnylam leverages specialty pharmacies for product distribution, crucial for RNAi therapeutics' unique needs. These pharmacies offer vital patient support, including education and adherence programs. This approach ensures optimal patient outcomes through specialized care and monitoring. In 2024, Alnylam's reliance on specialty pharmacies supported the successful launch of new therapies. The specialty pharmacy network is essential for Alnylam's business model.
Hospitals and Clinics
Alnylam's products are accessible in hospitals and clinics, facilitating direct administration to patients by healthcare providers. This channel is vital for patients needing close monitoring or facing specialty pharmacy access challenges. Alnylam collaborates with these institutions to ensure product availability and proper provider training. In 2024, Alnylam's sales in the US reached $1.2 billion, reflecting the importance of hospital and clinic channels.
Integrated Delivery Networks (IDNs)
Alnylam strategically collaborates with Integrated Delivery Networks (IDNs) to streamline its therapies into patient care. These partnerships are crucial for improving patient access to Alnylam's innovative treatments. Custom solutions are developed to meet the unique needs of each IDN, enhancing treatment effectiveness. In 2024, IDN partnerships significantly boosted Alnylam's market reach.
Direct-to-Physician Marketing
Alnylam's direct-to-physician marketing educates healthcare providers on RNAi therapeutics. This includes detailing, conferences, and educational programs. Direct engagement increases product awareness and clinical adoption. In 2024, Alnylam's marketing spend was significant. This strategy is vital for driving revenue growth.
- In 2024, Alnylam's R&D expenses were $1.2 billion, reflecting continued investment in innovation.
- Alnylam's product sales in 2024 were approximately $1.2 billion.
- Key products like Onpattro and Givlaari are promoted through these channels.
- Alnylam's market capitalization in late 2024 was around $20 billion.
Global Distribution Network
Alnylam's global distribution network is key for patient access worldwide. They use local distributors and logistics partners. This network helps reach more patients and boosts sales. Alnylam's global sales in 2024 were approximately $1.2 billion.
- Partnerships with distributors help reach various markets.
- Logistics are managed for efficient delivery.
- This supports a wider patient reach globally.
- Increased sales show the network's effectiveness.
Sales Surge: How Distribution Channels Boosted Revenue
Alnylam uses specialty pharmacies, hospitals, clinics, and IDNs for product distribution. Direct-to-physician marketing educates healthcare providers. A global network helps reach more patients. In 2024, global sales were ~$1.2B, showing channel effectiveness.
| Channel | Description | 2024 Impact |
|---|---|---|
| Specialty Pharmacies | Provide patient support and distribution. | Supports therapy launches. |
| Hospitals & Clinics | Direct administration by providers. | ~$1.2B sales in the US. |
| IDNs | Partnerships streamline care. | Boosted market reach. |
| Direct-to-Physician | Educates healthcare providers. | Drives revenue growth. |
| Global Distribution | Reaches patients worldwide. | ~$1.2B in global sales. |
Customer Segments
Genetic Disease Patients
Alnylam's core customer segment includes individuals with rare genetic diseases, offering hope where treatments were scarce. These patients often have significant unmet needs, making them key beneficiaries of Alnylam's RNAi therapies. Alnylam aims to treat the genetic root of these diseases. In 2024, Alnylam's focus remained on conditions like ATTR amyloidosis. Its net product revenues reached $1.25 billion in 2024.
Cardio-Metabolic Disease Patients
Alnylam targets cardio-metabolic disease patients, including those with ATTR-CM and hypercholesterolemia. These individuals need treatments to manage their conditions and avoid severe health issues. RNAi therapeutics provide a new way to tackle these diseases. In 2024, ATTR-CM therapies generated significant revenue. The market for hypercholesterolemia treatments is substantial, with billions spent annually.
Healthcare Providers
Alnylam targets healthcare providers like doctors and pharmacists managing genetic diseases. They depend on Alnylam's therapies and educational materials. Alnylam offers training to ensure correct product use. In 2024, Alnylam's sales reached $1.2 billion, reflecting provider adoption.
Integrated Delivery Networks (IDNs)
Alnylam collaborates with Integrated Delivery Networks (IDNs) to incorporate its therapies into patient care, enhancing accessibility. IDNs, encompassing hospitals and clinics, offer coordinated healthcare. Alnylam tailors solutions to meet specific patient needs within these networks. In 2024, Alnylam's partnerships with IDNs expanded, improving patient reach.
- Alnylam's revenue in 2024 reached approximately $1.2 billion.
- IDNs represent a significant portion of Alnylam's sales.
- Partnerships with IDNs are crucial for market penetration.
- Alnylam's focus on rare diseases aligns with IDN strategies.
Payers and Insurers
Alnylam interacts with payers and insurers to guarantee patient access to its therapies. These entities are crucial in establishing coverage and reimbursement terms for Alnylam's products. The company strives to prove the value and cost-efficiency of its RNAi therapeutics to obtain favorable coverage decisions.
- In 2023, Alnylam's net product revenues reached $1.08 billion, reflecting strong demand and market access.
- Alnylam actively negotiates with payers to demonstrate the long-term value and clinical benefits of its treatments.
- Securing favorable reimbursement is vital for Alnylam's financial performance and patient reach.
- The company's success hinges on its ability to navigate the complex landscape of healthcare reimbursement.
Alnylam's $1.25B Revenue Driven by Diverse Customer Segments
Alnylam's customer segments encompass patients with rare genetic and cardio-metabolic diseases needing advanced therapies. They also include healthcare providers, IDNs, and payers. This broad approach ensures comprehensive market access and patient support. In 2024, Alnylam's revenue reached $1.25B.
| Customer Segment | Description | 2024 Impact |
|---|---|---|
| Patients | Individuals with rare genetic and cardio-metabolic diseases. | Benefit from targeted RNAi therapies. |
| Healthcare Providers | Doctors, pharmacists, and specialists. | Enable proper product usage. |
| Payers/Insurers | Entities ensuring therapy access and reimbursement. | Influence market reach through coverage decisions. |
Cost Structure
Research and Development Expenses
Alnylam's cost structure heavily involves Research and Development. A substantial part of their expenses covers the discovery, preclinical work, and clinical trials of RNAi therapeutics. In 2023, Alnylam invested $1.1 billion in R&D. These investments are crucial for pipeline maintenance and RNAi technology advancement.
Clinical Trial Costs
Alnylam's clinical trial costs are significant. These expenses cover patient enrollment, data analysis, and regulatory filings. In 2024, Alnylam's R&D spending, including clinical trials, was a major cost. Alnylam's financial reports detail these substantial investments in drug development.
Manufacturing and Supply Chain Costs
Alnylam's cost structure includes manufacturing and supply chain expenses for its RNAi therapeutics, covering siRNA production, formulation, and distribution. These costs are crucial for global patient access to their products. The company also manages costs related to providing commercial drug supplies, such as GalNAc material, to its collaborators.
Sales and Marketing Expenses
Alnylam's cost structure includes significant investments in sales and marketing to boost product visibility and market share. These efforts encompass sales team salaries, advertising campaigns, and participation in industry events. These expenses are key for driving revenue and ensuring market penetration. For instance, in 2024, Alnylam's selling, general and administrative expenses, which include sales and marketing, were substantial.
- 2024: Selling, general, and administrative expenses were a significant portion of total operating expenses.
- These costs are essential for product promotion and market education.
- The company allocates resources to various promotional activities.
- Sales and marketing efforts are critical for commercial success.
General and Administrative Expenses
Alnylam's general and administrative expenses cover essential operational costs. These include salaries, rent, insurance, and legal fees, crucial for compliance and function. In Q3 2024, Alnylam reported $69.9 million in G&A expenses. GAAP operating income includes stock-based compensation, a key consideration in financial analysis.
- G&A expenses are fundamental for Alnylam's operational framework.
- These expenses are vital for maintaining regulatory compliance.
- Stock-based compensation is factored into GAAP operating income.
- G&A spending was $69.9 million in Q3 2024.
Decoding the Financials: A Cost Breakdown
Alnylam's cost structure is characterized by significant R&D investments, reaching $1.1 billion in 2023, vital for advancing RNAi technology and clinical trials.
Manufacturing and supply chain expenses are essential for producing and distributing RNAi therapeutics globally, ensuring patient access.
Sales and marketing costs, including those for promotional activities, were a significant portion of operating expenses in 2024, supporting product visibility and market penetration.
General and administrative expenses, amounting to $69.9 million in Q3 2024, support overall operations and regulatory compliance.
| Cost Category | Description | 2023/2024 Data |
|---|---|---|
| R&D | Discovery, clinical trials | $1.1B (2023) |
| Manufacturing | Production, distribution | Ongoing costs |
| Sales & Marketing | Promotional activities | Significant portion of operating expenses (2024) |
| G&A | Operational expenses | $69.9M (Q3 2024) |
Revenue Streams
Product Sales
Alnylam's core revenue stream comes from selling its RNAi therapeutics. Key products like ONPATTRO and AMVUTTRA target rare genetic diseases. In 2024, product sales reached $1,646 million. This marked a 33% increase year-over-year, showing solid growth.
Collaboration and Licensing Agreements
Alnylam boosts revenue via partnerships and licensing deals. Collaborations with Sanofi, Vir Biotechnology, Regeneron, and Novartis are key. These agreements bring upfront, milestone, and royalty payments. In 2023, Alnylam's collaboration revenue was $377.4 million. This revenue stream strengthens Alnylam's financial position.
Royalties on Partnered Products
Alnylam's revenue streams include royalties from partnered products. Leqvio, commercialized by Novartis, generates royalties for Alnylam. This recurring revenue supports R&D. Alnylam could receive 15-30% royalties on fitusiran sales, if approved. In 2024, Alnylam's collaboration revenue was $110.9 million.
Government Grants and Funding
Alnylam benefits from government grants and funding, crucial for its research and development. These funds offer non-dilutive support, fueling the advancement of RNAi therapeutics. Government assistance complements Alnylam's revenue streams, strengthening its financial base. In 2023, research and development expenses were approximately $1.4 billion. These grants are essential for sustaining innovation.
- Government funding supports Alnylam's R&D efforts.
- Grants provide non-dilutive financial resources.
- Funding enhances Alnylam's revenue streams.
- R&D expenses were around $1.4B in 2023.
Other Revenue
Alnylam's "Other Revenue" stream encompasses diverse income sources beyond its core product sales. This includes revenue from intellectual property sales, consulting services, and research collaborations. These additional streams bolster the company's financial health. Specifically, Alnylam plans to offer further guidance on collaboration and royalty revenue alongside operating expenses during its Q4 and full-year 2024 earnings release.
- Collaboration revenue is a key component, with Alnylam engaging in partnerships to expand its reach.
- Royalty income contributes to the "Other Revenue" category.
- The company will provide specific forecasts for these revenue streams.
- Q4 and full-year 2024 earnings will provide updated financial details.
Alnylam's Revenue: Sales, Partnerships, and Royalties
Alnylam's revenue hinges on selling RNAi therapeutics like ONPATTRO, with 2024 sales at $1,646 million, up 33%. Partnerships with companies such as Sanofi generated $110.9 million in collaboration revenue in 2024. Royalties from products like Leqvio also boost revenue. Research and development expenses reached approximately $1.4 billion in 2023, supported by government funding.
| Revenue Stream | Description | 2024 Revenue (Approx.) |
|---|---|---|
| Product Sales | Sales of RNAi therapeutics | $1,646 million |
| Collaboration Revenue | Upfront, milestone, and royalty payments from partnerships | $110.9 million |
| Royalties | Income from partnered products (e.g., Leqvio) | N/A |
| Government Grants | Funding for research and development | N/A |
Business Model Canvas Data Sources
Alnylam's BMC leverages financial reports, market analysis, and patent filings. These inform the customer segments, value propositions, & costs.
